Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvs crawled time : 12:20 save search
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-04 (Crawled : 12:20) - precisionbiosciences.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.38%
H: 0.73%
C: 0.15%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: -0.95%
H: 0.0%
C: 0.0%
business update financial results
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
Published: 2023-07-12 (Crawled : 12:20) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: 0.26%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
hope beacon education novartis trial
Mammography Market is expected to display a steady growth of 8% due to the rise in research and development activities| UnivDatos Market Insights
Published: 2023-03-02 (Crawled : 12:20) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.23%
H: 1.48%
C: 1.32%
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.06%
HOLX | $76.71 -0.62% -0.63% 910K
|
Health Technology
|
| O: -0.52%
H: 1.89%
C: 1.82%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.52%
H: 0.23%
C: -1.15%
research expected growth market
Retinal drugs market size to increase by USD 7.27579 billion; North America to account for 42% of market growth - Technavio
Published: 2023-02-08 (Crawled : 12:20) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.72%
H: 0.52%
C: -0.08%
ALC | $79.57 -1.47% 0.0% 850K
|
Health Technology
|
| O: 0.28%
H: 0.21%
C: -0.41%
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
|
| O: 0.19%
H: 0.65%
C: -0.55%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
MGTX | $4.87 -1.22% -1.23% 110K
|
Health Technology
|
| O: -1.14%
H: 4.62%
C: -0.77%
america growth market
Lipid Based Formulations Global Market Report 2023: Featuring Novartis, AbbVie, F. Hoffmann-La Roche, Johnson & Johnson, Alnylam Pharmaceuticals & More
Published: 2023-01-27 (Crawled : 12:20) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.56%
H: 0.73%
C: 0.17%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.21%
H: 0.19%
C: -0.18%
pharmaceuticals global report market
Alzheimer’s Therapeutics market is projected to grow at a CAGR of 9.17% by 2032: Visiongain Reports Ltd
Published: 2022-12-13 (Crawled : 12:20) - biospace.com/
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 1.89%
H: 0.88%
C: -0.09%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.28%
H: 0.2%
C: -0.9%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.71%
H: 0.61%
C: 0.06%
BIIB | $201.91 4.52% 4.32% 3.2M
|
Health Technology
|
| O: 1.09%
H: 0.32%
C: -0.85%
therapeutics alzheimer’s market
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.82%
H: 0.83%
C: 0.56%
QURE | $4.57 -3.79% -3.94% 640K
|
Health Technology
|
| O: -2.13%
H: 4.15%
C: -0.56%
RARE F | $44.26 -1.88% -1.92% 670K
|
Health Technology
|
| O: 0.25%
H: 3.17%
C: -6.19%
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -1.88%
H: 4.96%
C: 0.17%
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -3.01%
H: 0.77%
C: -10.46%
financial results
Baxter Reports Second-Quarter 2022 Results
Published: 2022-07-28 (Crawled : 12:20) - biospace.com/
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.12%
H: 2.36%
C: 2.36%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.02%
H: 0.99%
C: 0.56%
BAX | $40.93 -0.22% 0.0% 2.1M
|
Health Technology
|
| O: -7.56%
H: 1.47%
C: -3.64%
results
Valued to be $12.9 Billion by 2026, Crohn`s Disease (CD) Therapy Slated for Robust Growth Worldwide
Published: 2022-06-27 (Crawled : 12:20) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.78%
H: 0.94%
C: 0.26%
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -4.88%
H: 1.04%
C: -1.25%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
disease therapy growth
Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market Report 2022 with Competitive Landscape Analysis of Eli Lily and Co; Novartis; Bristol-Myers Squibb; Roche Diagnostics; Sanofi
Published: 2022-06-17 (Crawled : 12:20) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.01%
H: 0.17%
C: 0.17%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.76%
H: 5.75%
C: 5.5%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: -0.64%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.74%
H: 0.52%
C: -3.23%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
active report roche sanofi market diagnostic
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
Published: 2022-06-12 (Crawled : 12:20) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
kymriah children novartis
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
Published: 2022-06-06 (Crawled : 12:20) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
tafinlar novartis
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
Published: 2021-06-06 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
disease nephropathy kidney rare igan
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
Published: 2021-05-01 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
potential injection macular diabetic diabetes
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.